Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses: 2015-2025

Historic Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $40.8 million.

  • Intellia Therapeutics' Accumulated Expenses fell 20.24% to $40.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year decrease of 20.24%. This contributed to the annual value of $55.4 million for FY2024, which is 17.40% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Accumulated Expenses of $40.8 million as of Q3 2025, which was down 1.71% from $41.6 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Accumulated Expenses registered a high of $67.0 million during Q4 2023, and its lowest value of $21.2 million during Q1 2021.
  • For the 3-year period, Intellia Therapeutics' Accumulated Expenses averaged around $48.9 million, with its median value being $45.1 million (2024).
  • Per our database at Business Quant, Intellia Therapeutics' Accumulated Expenses skyrocketed by 141.64% in 2021 and then fell by 20.24% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Accumulated Expenses (Quarterly) stood at $43.3 million in 2021, then surged by 40.56% to $60.9 million in 2022, then increased by 10.09% to $67.0 million in 2023, then declined by 17.40% to $55.4 million in 2024, then dropped by 20.24% to $40.8 million in 2025.
  • Its last three reported values are $40.8 million in Q3 2025, $41.6 million for Q2 2025, and $40.8 million during Q1 2025.